PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1358053
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1358053
Global thrombectomy devices market is estimated to be valued at US$ 1.68 Bn in 2023, and is expected to exhibit a CAGR of 7.5% during the forecast period (2023-2030).
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 1.68 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 7.50% | 2030 Value Projection: | US$ 2.78 Bn |
Thrombectomy refers to physical removal of soft thrombus from blood vessels. A thrombectomy device is easy to use, and it consistently opens blood vessels for the removal of blood clots. Use of thrombectomy devices can improve long-term neurological outcomes such as ischemic brain injury and others, by providing higher rates of procedural recanalization. Once recanalization starts, clot softens and partially dissolves, indicating clinical recovery. Thrombectomy devices can be used in patients, where pharmacological treatments such as thrombolysis are likely to be ineffective or inappropriate, in case of recent cardiovascular surgery or in patients taking oral anticoagulants. Mechanical aspiration thrombectomy devices are dual-lumen catheters that are passed across the culprit lesion over a standard 0.014-inch guidewire. Of the two lumens, the smaller lumen consists of the guidewire by using a rapid exchange monorail system. Peripheral thrombectomy is associated with peripheral arterial disease (PAD), acute limb ischemia (ALI), critical limb ischemia (CLI), chronic total occlusion (CTO), deep vein thrombosis (DVT), pulmonary embolism (PE), and other peripheral vascular disease (PVD).
Increasing product approvals by regulatory authorities such as U.S. Food and Drug Administration is expected to drive the global thrombectomy devices market growth over the forecast period. For instance, in May 2020, Control Medical Technology, LLC., a medical technology company, announced that the U.S. Food and Drug Administration had approved Aspire MAX 7 - 11F mechanical thrombectomy system that is designed to remove blood clots from the peripheral vessels. The Aspire MAX 7 - 11F mechanical thrombectomy system includes (20) new large-lumen, flexible, and kink-resistant catheters w/dilators powered by the Aspire Aspirator and/or an electromechanical pump.
Thrombectomy Devices Market Detailed Segmentation: